Procept BioRobotics Corp (NASDAQ: PRCT) on Friday, plunged -4.79% from the previous trading day, before settling in for the closing price of $34.48. Within the past 52 weeks, PRCT’s price has moved between $27.80 and $87.45.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -12.56%. The company achieved an average annual earnings per share of 13.67%. With a float of $53.81 million, this company’s outstanding shares have now reached $55.87 million.
Procept BioRobotics Corp (PRCT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Procept BioRobotics Corp is 3.70%, while institutional ownership is 104.23%. The most recent insider transaction that took place on Aug 13 ’25, was worth 785,138. In this transaction Director of this company bought 20,000 shares at a rate of $39.26, taking the stock ownership to the 863,159 shares. Before that another transaction happened on Jun 10 ’25, when Company’s Director sold 25,000 for $63.91, making the entire transaction worth $1,597,711. This insider now owns 64,363 shares in total.
Procept BioRobotics Corp (PRCT) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.35 earnings per share (EPS) for the period topping the consensus outlook (set at -0.35) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.42% during the next five years compared to -12.56% drop over the previous five years of trading.
Procept BioRobotics Corp (NASDAQ: PRCT) Trading Performance Indicators
Procept BioRobotics Corp (PRCT) is currently performing well based on its current performance indicators. A quick ratio of 7.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.54, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.14 in one year’s time.
